America's lead in biotechnology is slipping toward Beijing while an outdated FDA bureaucracy slows the cures patients need right now. A physician who has already helped strip an outdated warning off hormone therapy and push honest guidance on chronic disease is exactly the kind of leader who treats people like adults. Delay here is a gift to competitors and a loss for families waiting on treatment.